金吾财讯 | 强生(JNJ)公布，美国食品药品监督管理局 (FDA) 已授予 posdinemab 快速通道资格，posdinemab 是一种针对磷酸化 tau 的单克隆抗体 (mAb)，正在2b期“AuTonomy”研究中研究用于治疗早期阿尔茨海默病 (AD) 患者。内部发现的 mAb 已显示出针对接受治疗的 AD 患者脑脊液 (CSF) 中与疾病相关的磷酸化 tau 的潜力，并可阻止非临床疾病模型中 tau 聚集体的形成和扩散。
强生：Posdinemab和Tau主动免疫疗法获得美国FDA治疗阿尔茨海默病的快速通道认定
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha